EMVS and NMVS: how European verification actually works

The European Medicines Verification System is often described as pharmaceutical track and trace. It is not, and the difference matters in practice, because it decides which questions the system can answer.

The four steps

The mechanism set out by the Falsified Medicines Directive and its delegated regulation has four moving parts.

1. The manufacturer serialises: each pack gets a unique identifier, carried in a Data Matrix, made up of the product code, serial number, batch and expiry date.
2. The marketing authorisation holder’s data are uploaded to the European hub (EMVS), which passes them on to the national systems (NMVS) of the countries where the product will be sold.
3. At the point of supply to the public, the pharmacy or hospital scans the pack, the national system checks the identifier’s status, and the identifier is decommissioned when the pack is dispensed.
4. An alert is raised if the identifier is unknown, already decommissioned, or inconsistent in some other way.

What the system sees of the pack’s route

The system records two events reliably: the pack came into the system, and the pack left it. Most of what happens in between is invisible to it.

A pack is not scanned at every wholesaler, every border and every transfer. Under this end-to-end model, wholesalers verify only in defined, risk-based cases, such as returned packs or packs bought from another wholesaler rather than from the manufacturer (Article 20 of the delegated regulation). So the system can tell you that a given pack is authentic and has not already been dispensed. In the general case it cannot tell you which route the pack took.

That is deliberate. It keeps the burden on the supply chain proportionate. It also has two consequences people tend to overlook.

The first concerns recalls. The verification system gets you to a batch. Getting from a batch to particular cases or pallets needs aggregation data, and the European system does not require them.

The second concerns diversion in the middle of the chain. What the system catches is a falsified or duplicated identifier at the counter. Parallel imports, re-imports and repackaging are where the legal chain is most tangled, and they are also where the system sees least.

Why that is verification and not traceability

This gets mixed up all the time, pharmacies included, so it is worth spelling out. Serialisation puts a unique identifier on the pack, and verification checks that the identifier is genuine and still active. Traceability records which pack went to which patient. The delegated regulation requires the first two. The third is a separate decision, usually built into the dispensing software, and the regulation does not impose it.

Mixing them up leads to two recurring mistakes: assuming the European system can answer patient-level questions, and assuming that because a pharmacy scans packs, it has patient traceability. Neither is true.

The alert problem

Alerts are where the model meets reality. Most of them have nothing to do with falsified medicines. They are data problems: a batch uploaded late, a product code mismatch, a pack scanned twice, a decommission never reversed after a dispense was cancelled at the counter.

For a manufacturer the practical consequence is that alert handling is an operational process that needs people every day, not a deliverable that closes with the project. Its volume depends directly on the quality of your master data and the discipline of your upload process, both of which are settled at enterprise level long before a pharmacist scans anything.

What to take from it

If your question is is this pack genuine?, the European system answers it, at the point of dispense, and answers it well.

If your question is where has this pack been?, which cases are affected by this deviation? or which patient received it?, the answer has to come from your own aggregation and dispensing records, not from EMVS. Plan your systems with that in mind.

References

• Commission Delegated Regulation (EU) 2016/161, safety features on the packaging of medicinal products for human use
• Directive 2011/62/EU, the Falsified Medicines Directive